 BUFFALO, N.Y., June 04, 2021 GLOBE NEWSWIRE -- Athenex, Inc., NASDAQ: ATNX, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the Company presented data from a phase I pharmacokinetic study of oral docetaxel plus encequidar oral docetaxel and updated data from the phase III study of oral paclitaxel plus encequidar oral paclitaxel illustrating tumor responses by molecular subtype. The data are being presented in two posters at the American Society for Clinical Oncology 2021 ASCO2021 Virtual Scientific Program, being held from June 4th to June 8th, 2021. 